Alternaleaf (Montu)

What it is

Alternaleaf is a medical cannabis clinic that operates primarily online, connecting UK patients with specialist doctors who can assess them for a medical cannabis prescription. It runs on a subscription model — patients pay a recurring fee for ongoing access to consultations and prescription management, with the cost of the cannabis medicine itself paid separately to a pharmacy Weak / limited^[1][2].

Medical cannabis has been legal to prescribe in the UK since November 2018, but only by doctors on the General Medical Council's Specialist Register, and almost always as an 'unlicensed special' rather than a licensed medicine Strong evidence^[3][4]. Alternaleaf operates inside that framework — it is a private clinic, not an NHS service, and prescriptions remain rare on the NHS Strong evidence^[4].

Ownership and parent company

Alternaleaf is the clinic brand of Montu, a cannabis healthcare company founded in Australia in 2019 by Christopher Strauch. Montu's Australian operations include the Alternaleaf clinic and the Leafio pharmacy distribution arm, and the group expanded into the UK market with a UK-based Alternaleaf clinic Weak / limited^[1][5].

Montu has been reported as one of the larger private cannabis healthcare groups in Australia, and reporting in the Australian press has covered both rapid growth and regulatory scrutiny of telehealth cannabis prescribing models more broadly Weak / limited^[5][6]. Specific UK corporate structure (which legal entity holds the Alternaleaf UK clinic licence, directors, and shareholders) can be checked on Companies House before relying on any ownership claim.

Market and category focus

Alternaleaf sits in the UK private medical cannabis telehealth category, alongside clinics such as Sapphire Medical Clinics, Mamedica, Releaf, Lyphe (formerly The Medical Cannabis Clinics) and Curaleaf Clinic. These clinics typically:

• Screen patients online for eligibility (usually requiring a documented condition and prior failed treatments).
• Refer them to a specialist doctor for video consultation.
• Issue private prescriptions for unlicensed cannabis-based products for medicinal use (CBPMs), which are then dispensed by a partner pharmacy Strong evidence^[3][4].

Conditions commonly assessed across the sector include chronic pain, anxiety, PTSD, insomnia, and certain neurological conditions, though evidence quality varies by indication and NICE has been cautious about routine NHS prescribing outside of specific paediatric epilepsy and chemotherapy-induced nausea contexts Strong evidence^[4][7].

Notable products and services

Alternaleaf itself does not manufacture cannabis products. Its service offering is the clinical pathway: eligibility screening, specialist consultation, prescription, and repeat-prescription management on a subscription basis Weak / limited^[1][2].

The actual medicines a patient receives — typically dried cannabis flower or oils from licensed producers and importers — are dispensed by partner pharmacies and depend on what products are available on the UK unlicensed-special market at the time Strong evidence^[3]. Product availability, brand, cultivar, and price are not controlled by the clinic in the way a retail brand controls inventory, and supply has historically been volatile. This profile does not recommend Alternaleaf or any specific product.

Reputation, controversies, and regulatory context

Marketing materials and trade press in both Australia and the UK have described Montu/Alternaleaf as a fast-growing player, and the company has cited large patient numbers. These figures are self-reported and have not, to our knowledge, been independently audited Weak / limited^[5].

The broader telehealth cannabis prescribing model has drawn regulatory attention. In Australia, the Therapeutic Goods Administration (TGA) and the medical regulator AHPRA have publicly warned about advertising and prescribing practices at cannabis telehealth clinics generally, and have taken enforcement actions in the sector; reporting has named Montu among companies operating in that environment, though specific findings vary and should be checked directly with the regulators Weak / limited^[6][8].

In the UK, the relevant regulators are the Care Quality Commission (CQC) for clinic registration, the General Medical Council (GMC) for prescribers, the General Pharmaceutical Council (GPhC) for dispensing pharmacies, and the MHRA for medicines and advertising. Any UK Alternaleaf clinic must be CQC-registered to provide regulated activities; readers can verify current registration and inspection reports directly on the CQC website Strong evidence^[9].

As of the last-checked date, we are not aware of public UK enforcement action specifically against Alternaleaf, but absence of public action is not the same as endorsement.

Availability and legal-market notes

Alternaleaf operates in a legal medical context only. UK patients cannot buy cannabis products from Alternaleaf the way they would from a retail brand; they must go through a clinical assessment, and a specialist doctor decides whether a prescription is appropriate Strong evidence^[3][4]. Prescribed cannabis is a controlled drug under the Misuse of Drugs Regulations 2001 (as amended in 2018), with specific rules for prescribing, dispensing, and patient possession Strong evidence^[3].

Recreational cannabis remains illegal in the UK. A medical prescription does not authorise sharing, resale, or use outside the patient's own treatment.

What to verify before relying on brand claims

If you're considering Alternaleaf — or any UK medical cannabis clinic — these are checks worth doing yourself rather than trusting marketing:

• CQC registration and latest inspection report for the specific clinic entity ^[9].
• GMC specialist register status of the prescribing doctor (free public search).
• Companies House filings to confirm the UK operating entity, directors, and accounts.
• Subscription terms and cancellation policy in writing, including what happens to your prescription if you stop subscribing.
• Pharmacy partner: which pharmacy dispenses, GPhC registration, and whether you can use a different pharmacy.
• Total cost including subscription, consultation, and medicine — not just the headline subscription fee.
• Evidence for your specific condition: NICE guidance and your own GP's view, since clinic websites tend to emphasise potential benefits and underplay weak or absent evidence for many indications Strong evidence^[4][7].

Profile last checked: June 2024. Company structures, ownership, and regulatory status can change; verify before acting.

Sources

How this page was made